(Q35607538)

9 August 2017

1 reference

title

Clinical pharmacokinetics of galantamine (English)

1 reference

9 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Martin R Farlow

1

1 reference

9 August 2017

1 January 2003

1 reference

Clinical Pharmacokinetics

9 August 2017

1 reference

9 August 2017

42

1 reference

9 August 2017

15

1 reference

9 August 2017

1383-1392

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200342150-00005

9 August 2017

0 references

1 reference

12 December 2020

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

12 December 2020

Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans

1 reference

12 December 2020

Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition.

1 reference

12 December 2020

Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors.

1 reference

12 December 2020

Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution

1 reference

12 December 2020

Galantamine Population Pharmacokinetics in Patients with Alzheimer's Disease: Modeling and Simulations

1 reference

12 December 2020

Nicotinic acetylcholine involvement in cognitive function in animals

1 reference

12 December 2020

1 reference

12 December 2020

Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells

1 reference

12 December 2020

Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans.

1 reference

12 December 2020

Chronic inhibition of alpha4beta2 nicotinic receptors in the ventral hippocampus of rats: impacts on memory and nicotine response

1 reference

12 December 2020

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

12 December 2020

Muscarinic and nicotinic contributions to cognitive function and cortical blood flow

1 reference

12 December 2020

Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevance.

1 reference

12 December 2020

Comparison of galanthamine with neostigmine for reversal of d-tubocurarine neuromuscular blockade in man

1 reference

12 December 2020

Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks.

1 reference

12 December 2020

Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR

1 reference

12 December 2020

Galanthamine, an acetylcholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice

1 reference

12 December 2020

Effects of the acetylcholinesterase inhibitor ENA-713 on ischemia-induced changes in acetylcholine and aromatic amine levels in the gerbil brain.

1 reference

12 December 2020

The cholinergic hypothesis of geriatric memory dysfunction

1 reference

12 December 2020

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

1 reference

12 December 2020

The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system

1 reference

12 December 2020

Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats.

1 reference

12 December 2020

Physostigmine, galanthamine and codeine act as ‘noncompetitive nicotinic receptor agonists’ on clonal rat pheochromocytoma cells

1 reference

12 December 2020

Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats.

1 reference

12 December 2020

Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons.

1 reference

12 December 2020

Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.

1 reference

12 December 2020

Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.

1 reference

12 December 2020

Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands

1 reference

12 December 2020

In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers.

1 reference

12 December 2020

Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine

1 reference

12 December 2020

Alkaloid content of different bulb parts of Narcissus cv. Ice Follies

1 reference

12 December 2020

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

1 reference

12 December 2020

Galantamine: Effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning

1 reference

12 December 2020

Estimated prevalence of Alzheimer's disease in the United States

1 reference

12 December 2020

Narcissus nivalis: A New Source of Galanthamine1

1 reference

12 December 2020

Experiences with galanthamine hydrobromide as curare antagonist

1 reference

12 December 2020

Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.

1 reference

12 December 2020

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society

1 reference

12 December 2020

Development of nicotinic drug therapy for cognitive disorders.

1 reference

12 December 2020

Reversal of Central Anticholinergic Syndrome by Galanthamine

1 reference

12 December 2020

Galantamine: a review of its use in Alzheimer's disease

1 reference

12 December 2020

Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function.

1 reference

12 December 2020

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

12 December 2020

Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease

1 reference

12 December 2020

Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor alpha-polypeptide

1 reference

12 December 2020

The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6

1 reference

12 December 2020

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

1 reference

12 December 2020

Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning

1 reference

12 December 2020

10.2165/00003088-200342150-00005

Identifiers

DOI

1 reference

PubMed ID

14674789

Dimensions Publication ID

9 August 2017

1014500514

0 references

Fatcat ID

release_i26ifnaihrfvdibpunkhsun4xa

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/i26ifnaihrfvdibpunkhsun4xa

24 November 2022

mapped directly with Wikidata item

PubMed ID

14674789

1 reference

PubMed ID

14674789